Two - Half Day Sessions

Click Here for the Schedule and Abstracts

What Molecular Forces Could Possibly be Involved in
    Stabilizing the Topoisomerase I-DNA-Inhibitor Ternary
    Cleavage Complex and What Do the Answers Tell Us About
    How to Design More Effective Topoisomerase I Inhibitors?

Mark Cushman

Department of Medicinal Chemistry and Molecular Pharmacology
Purdue University

Rational Drug Design. Where it Has Been and
    Where Might It Go in the 21st Century

Daniel H. Rich

School of Pharmacy
University of Wisconsin-Madison

The Search for the Next Generation of HIV Protease Inhibitors

David DeGoey

Abbott Laboratories

The Design of Hepatitis C Protease Inhibitors
    and the Discovery of VX-950

Robert B. Perni

Vertex Pharmaceuticals

Click Here for the Schedule and Abstracts

Targeting Heterodimeric and Protein-Coupled Receptors as an Added
    Dimension in Drug Design. Opioid Receptors as Proof of Concept

Philip S. Portoghese

Department of Medicinal Chemistry
University of Minnesota

Design of Potent and Selective 2-Aminobenzimidazole-Based
    p38MAP Kinase Inhibitors with Excellent in Vivo Efficacy

Mary M. Mader

Eli Lilly

NO New Strategies in Modern Medicinal Chemistry:
    Nitrates and NO (Nitric Oxide) Chimeras

Gregory R. J. Thatcher

Department of Medicinal Chemistry and Pharmcognosy
University of Illinois-Chicago

Targeting Protein-protein Interactions for the Treatment of
    Cancer: Discovery of Bcl-2 Family Protein Inhibitors

Steven Elmore

Abbott Laboratories